Livzon Pharma’s LZM012 Meets Phase III Endpoint for Psoriasis Treatment
China-Based Livzon Pharmaceutical Group, a holding subsidiary of Joincare Pharmaceutical (SHA: 600380) announced that the...
SHA: 600380
Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China
China-based Brii Biosciences Ltd (HKG: 2137) announced a licensing agreement with compatriot firm Joincare Pharmaceutical...
Joincare Pharma Gets NMPA Green Light for Pediatric Influenza Drug JKN2301
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced that it has received clinical...
Joincare Pharmaceutical Plans to Acquire 64.81% Stake in Imexpharm for USD 220M
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced plans to acquire a 64.81%...
Joincare Pharmaceutical’s JKN2403 Gains NMPA Approval for COPD Clinical Trials
China-based Jo2006incare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) is set to advance its Category...
E-nitiate Biopharmaceuticals Strikes Licensing Deal with Joincare for QY101 Inhaler Rights
China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a joint venture between VivaVision Biotech and Betta Pharmaceuticals...
Joincare Pharmaceutical Secures NMPA Approval for Triptorelin Microspheres to Treat Endometriosis
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...
Joincare Pharmaceutical Receives NMPA Approval for Generic Seretide
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a leading pharmaceutical company based in China,...
Joincare Pharmaceutical’s TG-1000 Shows Promise in Phase III Flu Treatment Trial
Joincare Pharmaceutical Group Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has reportedly completed the...
Joincare Pharmaceuticals Secures Rights to Bayer’s Respiratory Drug in China
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a...
Joincare Pharmaceuticals Gets Green Light for Semaglutide Biosimilar Clinical Trial
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical entity, has announced that...
Joincare Pharmaceutical Group Secures USD 100 Million Loan from IFC for Expansion
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced securing...
Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101
Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement...
Joincare Pharmaceutical Partners with QYuns Therapeutics for Exclusive Rights to QX008N in China and Hong Kong
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a...
Joincare Pharmaceutical’s Partner Fermion Gets NMPA Green Light for Pain Drug Clinical Study
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced that...
Joincare Pharmaceutical Initiates Phase III Study for Anti-IL-17A mAb in Plaque Psoriasis
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced the initiation of a...
Joincare Pharmaceutical Receives NMPA Approval for Triptorelin Microspheres for Prostate Cancer
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced that...
Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with...
Joincare’s Generic Seretide Accepted for NMPA Review
China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that the market filing...
Joincare’s Biosimilar Tocilizumab Approved for Marketing in China
China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that its subsidiary Zhuhai...